louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02853058: Uterine Artery Pulsatility Index and Materno Fetal Outcomes
Official title: Uterine Artery Pulsatility Index During Labor After 34 Weeks in the Prediction of Materno Fetal Outcomes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Labor Complication
Keywords: stillbirth
hemorrhage
Lead sponsor: University Tunis El Manar
Sponsor class: OTHER
First posted: 2016-08-02
Enrollment: 600
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: High Uterine artery index pulsatility (PI) is associated with small for gestationnal age but also with stillbirth and distress during labor.

Detailed description: measures of Uterine artery PI is made with transabdominal color flow during labor. The right and left uterine arteries are visualized at the crossover wth the external iliac arteries. PI is measured and the mean PI of the two vessels is calculated and expressed as multiple of the median (MoM).The outcomes stillbirth, distress and vaginal or cesarean delivery, apgar sore \<7 at 5 minutes, birth weight and maternal outcomes: preeclampsia, hemorrhage and other complications are noted.

Eligibility criteria: Inclusion Criteria:

* gestationnal age \>=34 weeks
* during labor

Exclusion Criteria:

* elective cesarean even if labor
* non elligible ultrasound criteria of good measurement of uterine artery PI

Primary outcomes:
measure: right uterine artery pulsatility index measurement
timeFrame: 15 minutes
measure: left uterine artery pulsatility index measurement
timeFrame: 15 minutes
Secondary outcomes:
measure: maternal outcome
timeFrame: 2 days
measure: small for gestationnal age (SGA)
timeFrame: 1 day
measure: Apgar Score<7
timeFrame: 1 day
measure: distress
timeFrame: 1 day
Other outcomes:
Locations:
city: Bizerte
country: Tunisia
facility: University Hospital Bougatfa
Study officials:
affiliation: University Tunis El Manar
name: AMIRA AYACHI, Ph D
role: STUDY_CHAIR
References:
citation: Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Uterine artery pulsatility index at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2016 Mar;47(3):308-15. doi: 10.1002/uog.14898. Epub 2016 Feb 1.
Clinical trial NCT02195258: Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis
Official title: Pharmacogenetic of the Salbutamol Efficacy in Asthma Crisis for Children in Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: Hôpital Necker-Enfants Malades
Sponsor class: OTHER
First posted: 2014-07-21
Enrollment: 95
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children 6-16 years old asthmatic patients consulting for an exacerbation in a pediatric emergency department

Brief summary: this study is designed to identify the genetic factors which can be implicated in the salbutamol responsiveness for asthmatic children in pediatric emergency department

Detailed description: Patients from 6 to 16 years old consulting for an acute asthma exacerbation and receiving a treatment by salbutamol according to the usual care could be recruited.Saliva from patient were collected using Oragen®.DNA OG-500 kit or swabs.Based on literature review, four SNP were chosen:ADBR2 gene), ARG gene, and GSNOR gene.

Eligibility criteria: Inclusion Criteria:

* children
* 6-16 years old
* asthmatic patients
* consulting for an exacerbation in a pediatric emergency department
* parental informed consent

Exclusion Criteria:

* comorbidity
* peak flow no available
* pneumonia

Primary outcomes:
measure: pre- and post-bronchodilator FEV1 value (BDR = 100 x [post-FEV1 - pre-FEV1]/pre-FEV1)
timeFrame: Day 0
Secondary outcomes:
measure: polymorphism on the response delay
timeFrame: Day 0
Other outcomes:
Locations:
city: Paris
country: France
facility: Necker Enfants Malades Hospital
Study officials:
affiliation: APHP
name: Hélène Chappuy, MDPhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01296958: Targeted Screening for Taenia Solium Tapeworms
Official title: Targeted Screening for Taenia Solium Tapeworms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Taenia Solium Taeniasis
Keywords: Taenia solium
cysticercosis
neurocysticercosis
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: National University of San Marcos, Peru
name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2011-02-16
Enrollment: 1811
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.


Eligibility criteria: Inclusion Criteria:

* All community members are eligible

Exclusion Criteria:

* Inability to provide informed consent

Primary outcomes:
measure: Porcine seroprevalence
timeFrame: Every 4 months
Secondary outcomes:
measure: Intestinal tapeworm prevalence
timeFrame: 16 months
Other outcomes:
Locations:
city: Lima
country: Peru
facility: San Marcos University
Study officials:
affiliation: Oregon Health and Science University
name: Seth E ONeal, MD MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: San Marcos University School of Veterinary Medicine
name: Armando Gonzalez, DVM PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03038958: Comparison of Hyperbaric Prilocaine With Chloroprocaine for Intrathecal Anaesthesia in Day Case Knee Arthroscopy
Official title: Comparison of Hyperbaric Prilocaine With Chloroprocaine for Intrathecal Anaesthesia in Day Case Knee Arthroscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Knee Arthroscopy
Spinal Anesthesia
Keywords: Local Anaesthetic
spinal anesthesia
Knee arthroscopy
Lead sponsor: Centre Hospitalier Universitaire Saint Pierre
Sponsor class: OTHER
Collaborators: name: Hôpital de Braine-l'Alleud
First posted: 2017-02-01
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares intrathecal 1% plain chloroprocaine with intrathecal 2% hyperbaric prilocaine for patients undergoing ambulatory knee arthroscopy in terms of efficacy and side effects


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiology physical status (ASA) ≤ III
* Age 18-80 year
* Height between 160 and 185 cm
* Signed informed consent obtained prior to any study specific assessments and procedures

Exclusion Criteria:

* Cardiac pathology (such as Heart failure, Aortic stenosis)
* Coagulation disorders (INR\>1.3, platelet \< 80 000/mm3)
* Known allergy to local anaesthetics
* Disagreement of the patient

Primary outcomes:
measure: Duration of sensory block
timeFrame: Until complete release of sensory block
Secondary outcomes:
measure: Onset time of sensory block
timeFrame: up to 30 minutes
measure: Onset time of motor block
timeFrame: up to 30 minutes
measure: Duration of motor block
timeFrame: Until complete regression of motor block
measure: Pain assessed by Visual Analog Scale
timeFrame: up to 24 hours
measure: Side-effects (hypotension, bradycardia, urinary retention)
timeFrame: up to 24 hours
Other outcomes:
Locations:
city: Braine-l'Alleud
country: Belgium
facility: Braine-l'Alleud Hospital
city: Brussels Capital Region
country: Belgium
facility: CHU Saint-Pierre
Study officials:
affiliation: Université Libre de Bruxelles (ULB), Braine-l'Alleud Hospital
name: Emmanuel Guntz, MD
role: STUDY_DIRECTOR
affiliation: University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)
name: Panayota Kapessidou, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01878058: Identifying Prostate Brachytherapy Seeds Using MRI
Official title: Identifying Prostate Brachytherapy Seeds Using MRI
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Keywords: Prostate cancer
Brachytherapy
Seed implant
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Princess Margaret Hospital, Canada
First posted: 2013-06-14
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study will look at the feasibility of using a type of Magnetic Resonance Imaging called Susceptibility Weighted Imaging (SWI) to detect your implanted radioactive seeds. Researchers hope that using SWI will eliminate the need to use CT imaging to detect your implanted radioactive seeds.

This study will also see if the MRI seed detection is as effective as current standard practice of seed detection (routine MRI and CT imaging). This technique would be beneficial for brachytherapy without the need to fuse the MRI and CT images, as is done currently.


Eligibility criteria: Inclusion Criteria:

1. At least 18 years old
2. Histologic diagnosis of adenocarcinoma of the prostate
3. No contraindications for Pelvic body MRI
4. Patients undergoing LDR brachytherapy at PMH and scheduled for post implant analysis with CT-MR (standard at PMH)
5. Ability to provide written informed consent to participate in the study

Exclusion Criteria:

1. Contraindication for Pelvic body MRI
2. Patient not willing/consenting for this study

Primary outcomes:
measure: Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce registration errors
timeFrame: 6 months
measure: Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce planning time for the post-implant plan
timeFrame: 6 months
measure: Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will eliminate the CT scan of the patient.
timeFrame: 6 months
Secondary outcomes:
measure: Compare the differences in MR seed identification using the MR pulse sequence vs. CT images.
timeFrame: 6 months
Other outcomes:
measure: Compare the prostate dosimetry (V100 and D90) in prostate low dose rate therapy using MR alone with CT/MR fusion.
timeFrame: 6 months
Locations:
city: Toronto
country: Canada
facility: University Health Network, The Princess Margaret
state: Ontario
Study officials:
affiliation: University Health Network, The Princess Margaret
name: Saibishkumar Elantholiparameswaran, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00536458: Treatment of Localized Low Grade Lymphomas
Official title: Phase III Study of Treatment of Localized Lymphomas: Radiotherapy Versus Radio-Chemotherapie
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lymphoma, Low-Grade
Keywords: localized low grade lymphoma
Chemotherapy
Radiotherapy
Molecular analyses
primary
Lead sponsor: French Innovative Leukemia Organisation
Sponsor class: OTHER
First posted: 2007-09-27
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare localiezd radiotherapy to localized radiotherapy followed by 6 cycles of chemotherapy in the treatment of localiezd low grade lymphoma

Detailed description: The standard treatment ol localized low grade lymphomas is Radiotherapy alone can offer long term remissions to some patients .

No study have clearly demonstrated the interest of chemotherapy. The purpose of the study is to determine wether prednisone administrated after first line local radiotherapy (30 GY) can pre in the treatment of localized low grade lymphomas of adult patients

Eligibility criteria: Inclusion Criteria:

* Low grade lymphoma defined according to the Ann Arbor classification
* localized

Exclusion Criteria:

* Subjects unable to signed informed consent
* Pregnancy

Primary outcomes:
measure: failure free survival at 5 years
timeFrame: 5 years
Secondary outcomes:
measure: overall survival at 5 years
timeFrame: 5 years
measure: response rates at the end of the treatment
timeFrame: 6 months
measure: prognstic value of molecular analyses in blood and marrow
timeFrame: 6 months
Other outcomes:
Locations:
city: Besancon
country: France
facility: Regional university hospital
Study officials:
affiliation: French Innovative Leukemia Organisation
name: eric DECONINCK, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05151458: Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease
Official title: Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Inflammatory Bowel Diseases
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-12-09
Enrollment: 80
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with IBD

Brief summary: Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and plasma cells.


Eligibility criteria: Inclusion Criteria: IBD patients diagnosed by endoscopy.

Male and female gender. Disease activity proven clinically and endoscopy . Assiut university hospital patients

Exclusion Criteria:

* Patients who refuse to contribute in this study Pregnancy and breast feeding Cancer patients Renal pathology Diabetes Mellitus Cardiovascular patients Pancreatitis COPD patients

Primary outcomes:
measure: test the sensitivity and specificity of using NGAL in diagnosis of IBD
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012 May;47(5):519-30. doi: 10.1007/s00535-011-0516-5. Epub 2011 Dec 27.
citation: Nakov R. New markers in ulcerative colitis. Clin Chim Acta. 2019 Oct;497:141-146. doi: 10.1016/j.cca.2019.07.033. Epub 2019 Jul 27.
Clinical trial NCT03651258: Facilitate the Transition From Passive Feeding to Active Feeding in Preterm Infants Through Early Play
Official title: Facilitate the Transition From Passive Feeding to Active Feeding in Preterm Infants Through Early Play
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Immature Newborn
Feeding Behavior
Keywords: Feeding Behavior
Lead sponsor: Centre Hospitalier Intercommunal Creteil
Sponsor class: OTHER
First posted: 2018-08-29
Enrollment: 59
Sex: ALL
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Premate newborn with an age inferior to 32 weeks of amenorrhea at birth

Brief summary: The approach described here is based both on theoretical concepts and on the work of several teams of researchers. By positioning the baby and the appropriate adult, a speech bath, a sustained look and an expressive face, it is hypothesized that this early communication exercise will significantly improve the transition from passive feeding, active feeding of the premature child, from a qualitative and quantitative point of view.


Eligibility criteria: Inclusion Criteria:

* Age of child at birth: \<32 WA justified by the greater prevalence of oral disorders in these children.
* Age of the child at the start of the study: 35 WA, ie at the beginning of the establishment of active feeding within the unit.

Exclusion Criteria:

* Children with oral malformations
* Contra-indication to the realization to the ALIJEU (infection in progress, hemodynamic instability, etc.)
* Medical contraindications to oral diet

Primary outcomes:
measure: age at the stoppage of enteral nutrition
timeFrame: 37 weeks of gestation
Secondary outcomes:
measure: Duration of feeding
timeFrame: 37 weeks of gestation
measure: Quantities drunk
timeFrame: 37 weeks of gestation
measure: Awakening
timeFrame: 37 weeks of gestation
measure: Visual analogic scale for Satisfaction from 0 to 10
timeFrame: 37 weeks of gestation
Other outcomes:
Locations:
city: Créteil
country: France
facility: CHI Créteil
state: Ile De France
Study officials:
References:
Clinical trial NCT01624558: Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
Official title: Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Malignant Hyperthermia
Keywords: malignant hyperthermia
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2012-06-20
Enrollment: 0
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Malignant hyperthermia is a potentially fatal inherited disorder triggered by exposure to volatile anesthetic gases, most commonly recognized in children during anesthesia. Carbon filters have been used to scavenge various gases. A new carbon filter (Vapor Clean, Dynasthetics, LLC, Salt Lake City, Utah) with a 510(k) clearance specifically for scavenging anesthetic gases is being marketed, though the filter itself has never been studied in vivo. Bench studies conducted by the manufacturer of the product demonstrate it is extremely effective in reducing the volatile gas output from an anesthesia machine within 2 minutes. This pilot study will measure the effect on volatile gas concentration in non-malignant hyperthermia susceptible patients. Twelve (12) patients will undergo standard anesthetic induction using inhalational anesthetic (Sevoflurane®) and maintained on 3% for 30 minutes to attain steady state concentrations.1 At that time, a total intravenous anesthetic technique will be started and maintained throughout the case. Simultaneously a Vapor Clean filterset will be placed in the breathing circuit (inspiratory and expiratory limbs). Volatile gas concentration will be measured and recorded. This research will determine the feasibility of using this carbon filter to quickly reduce the breathing circuit gas concentration of volatile anesthetic in the clinical setting. This is fundamental in establishing this as a key life saving measure in eliminating the stimulus in a malignant hyperthermia event.

Detailed description: see above.

Eligibility criteria: Inclusion Criteria:

* healthy ASA PS I or II children 2 years to 16 years old
* having general anesthesia for approximately 1 hour or more

Exclusion Criteria:

* malignant hyperthermia susceptible patients (personal or family history)
* patients with known neuromuscular disorders at high risk of malignant hyperthermia (e.g., muscular dystrophy)
* egg or soy allergy
* patient or parent refusal
* pregnant patients

Primary outcomes:
measure: Time to reduce Concentration of Volatile Anesthetic to <5ppm
timeFrame: every two minutes after filter applied until concentration is <5ppm or 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Johns Hopkins University
name: Robert S Greenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07027358: Clinical Investigation Evaluating the Use of NETSmart Solution , Incorporated to NETSoins Software, in the Care and Support of Elderly People Living in Nursing Homes
Official title: Clinical Investigation Evaluating the Use of NETSmart Solution , Incorporated to NETSoins Software, in the Care and Support of Elderly People Living in Nursing Homes
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pressure Injury
Fall Prevention
Undernutrition
Drug Interaction
Lead sponsor: Teranga Software
Sponsor class: INDUSTRY
Collaborators: name: RCTs
First posted: 2025-06-18
Enrollment: 30
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: NETSmart software is designed to help doctors, nurses and care assistants adapt the care of elderly people living in nursing homes to the following risks:

* pressure injuries
* undernutrition
* interactions between different drugs
* falls. The software analyzes the information in your medical records, alerts your medical team to any points of vigilance, and suggests appropriate recommendations.

The study comprises 2 distinct phases:

* An initial 4-month phase, during which the medical staff will simply assess whether the NETSmart software's recommendations are relevant, without changing their current practice, i.e. they will continue to care for you as usual;
* A second 6-month phase, during which your caregivers will follow the software's recommendations if they feel they are relevant, and potentially adapt your care.


Eligibility criteria: Inclusion Criteria:

* Male or female, at least 70 years old
* Permanent resident at an investigation site for at least 6 months.
* Considered an at-risk patient, i.e. meeting at least one of the following criteria :
* Braden score \< 16
* At risk of pressure ulcer according to the investigator's judgment
* At risk of undernutrition as judged by the investigator
* Undergoing at least 6 drug treatments
* At risk of falls as judged by the investigator
* Affiliated with the French social security system
* Having given informed, dated and signed consent to participate in the investigation

Exclusion Criteria:

* Patient with a life expectancy of less than 2 months as judged by the investigator
* Patient who is participating or has participated in another investigation or study involving the use of a medical device or drug within 30 days prior to inclusion

Primary outcomes:
measure: Percentage of clinically relevant recommandations provided by NETSmart
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Etang-sur-Arroux
country: France
facility: Maison de Famille Bourgogne
Study officials:
References: